PET Scanning in Staging and Evaluation of Response to Treatment in Lung Cancer

  • Michael P. MacManus
  • Rodney J. Hicks
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)


Positron Emission Tomography Standardise Uptake Value Radiat Oncol Biol Phys Positron Emission Tomography Scanning Radical Radiotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abou-Zied M, Zubeldia J, Nabi H (2000) 30. Follow-up of patients with single pulmonary nodules and negative 18f-fluorodeoxyglucose positron emission tomography scans. Clin Positron Imaging 3:184CrossRefPubMedGoogle Scholar
  2. Ackerly T, Andrews J, Ball D, Binns D, Clark R, D'Costa I, et al. (2002) Display of positron emission tomography with Cadplan. Australas Phys Eng Sci Med 25:67–77PubMedGoogle Scholar
  3. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, et al. (2002) An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 73:259–264CrossRefPubMedGoogle Scholar
  4. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H et al. (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229:526–533PubMedGoogle Scholar
  5. Ball D, Smith J, Wirth A, Mac Manus M (2002) Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 54:1007–1013CrossRefPubMedGoogle Scholar
  6. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. (2003) Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44:1200–1209PubMedGoogle Scholar
  7. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. (2003) Imaging proliferation in lung tumors with PET: 18F-FT versus 18F-FDG. J Nucl Med 44:1426–1431PubMedGoogle Scholar
  8. Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P (1996) Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 23:20420–20426CrossRefGoogle Scholar
  9. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P (1998) Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244–1247CrossRefPubMedGoogle Scholar
  10. Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N, et al. (1999) Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 14:1376–1380CrossRefPubMedGoogle Scholar
  11. Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, et al. (2002) Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:1024–1035CrossRefPubMedGoogle Scholar
  12. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853–863CrossRefPubMedGoogle Scholar
  13. Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, et al. (2002) FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 36:297–301CrossRefPubMedGoogle Scholar
  14. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92–96PubMedGoogle Scholar
  15. Dunagan D, Chin R, Jr., McCain T, Case L, Harkness B, Oaks T, et al. (2001) Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest 119:333–339CrossRefPubMedGoogle Scholar
  16. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL (1999) Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology 213:530–536PubMedGoogle Scholar
  17. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. (2000) Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27:861–866CrossRefPubMedGoogle Scholar
  18. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, et al. (2002) Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51–60CrossRefPubMedGoogle Scholar
  19. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, et al. (2002) FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 29:804–808PubMedGoogle Scholar
  20. Farrell MA, McAdams HP, Herndon JE, Patz EF, Jr. (2000) Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 215:886–890PubMedGoogle Scholar
  21. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D (2003) Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5:26–31CrossRefPubMedGoogle Scholar
  22. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. (2000) Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117–121PubMedGoogle Scholar
  23. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914–924CrossRefPubMedGoogle Scholar
  24. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239–253CrossRefPubMedGoogle Scholar
  25. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK (2002) Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 29:1393–1398PubMedGoogle Scholar
  26. Hara T, Inagaki K, Kosaka N, Morita T (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 41:1507–1513PubMedGoogle Scholar
  27. Hicks RJ, MacManus MP (2003) 18F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact? J Nucl Med 44:30–32PubMedGoogle Scholar
  28. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. (2001) The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42:1605–1613PubMedGoogle Scholar
  29. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. (2000) FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 41:85–92PubMedGoogle Scholar
  30. Higashi K, Ueda Y, Sakuma T, Seki H, Oguchi M, Taniguchi M, et al. (2001) Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. J Nucl Med 42:1489–1496PubMedGoogle Scholar
  31. Hoekstra CJ, Hoekstra OS, Stroobants SG, Vansteenkiste J, Nuyts J, Smit EF, et al. (2002) Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304–1309PubMedGoogle Scholar
  32. Hutton BF, Braun M, Thurfjell L, Lau DY (2002) Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging 29:559–577CrossRefPubMedGoogle Scholar
  33. Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. (2001) Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 19:111–118PubMedGoogle Scholar
  34. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W, et al. (1998) The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19:167–177CrossRefPubMedGoogle Scholar
  35. Lever AM, Henderson D, Ellis DA, Corris PA, Gilmartin JJ (1984) Radiation fibrosis mimicking local recurrence in small cell carcinoma of the bronchus. Br J Radiol 57:178–180PubMedGoogle Scholar
  36. MacManus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E et al. (2001a) F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 92:886–895CrossRefPubMedGoogle Scholar
  37. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. (2001b) High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 50:287–293CrossRefPubMedGoogle Scholar
  38. MacManus MP, Hicks RJ, Ball DL, Ciavarella F, Binns D, Hogg A, et al. (2001c) Imaging with F-18 FDG PET is superior to T1-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy. Australas Radiol 45:483–490CrossRefPubMedGoogle Scholar
  39. MacManus MP, Hicks R, Fisher R, Rischin D, Michael M, Wirth A, et al. (2003a) FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy-survival correlates with metastatic disease burden. Acta Oncol 42:48–54CrossRefPubMedGoogle Scholar
  40. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. (2003b) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285–1292CrossRefPubMedGoogle Scholar
  41. Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, et al. (2002) The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52:339–350CrossRefPubMedGoogle Scholar
  42. Mankoff DA, Shields AF, Link JM, Graham MM, Muzi M, Peterson LM, et al. (1999) Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med 40:614–624PubMedGoogle Scholar
  43. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. (1999) Staging non-small cell lung cancer with whole-body PET. Radiology 212:803–809PubMedGoogle Scholar
  44. Mountain CF, Lukeman JM, Hammar SP, Chamberlain DW, Coulson WF, Page DL, et al. (1987) Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 35:147–156PubMedGoogle Scholar
  45. Nettelbladt OS, Sundin AE, Valind SO, Gustafsson GR, Lamberg K, Langstrom B, et al. (1998) Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 39:640–647PubMedGoogle Scholar
  46. Pandit N, Gonen M, Krug L, Larson SM (2003) Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30:78–84PubMedGoogle Scholar
  47. Pieterman RM, Que TH, Elsinga PH, Pruim J, van Putten JW, Willemsen AT, et al. (2002) Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 43:167–172PubMedGoogle Scholar
  48. Pitman AG, Hicks RJ, Kalff V, Binns DS, Ware RE, McKenzie AF, et al. (2001) Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. Med J Aust 175:303–307PubMedGoogle Scholar
  49. Pitman AG, Hicks RJ, Binns DS, Ware RE, Kalff V, McKenzie AF, et al. (2002) Performance of sodium iodide based (18)F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses. Br J Radiol 75:114–121PubMedGoogle Scholar
  50. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P (2001) PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 20:468–474CrossRefPubMedGoogle Scholar
  51. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Koga H, Hayashi K, et al. (2001) Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung. Ann Nucl Med 15:425–431PubMedGoogle Scholar
  52. Schmucking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C, et al. (2003) Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res 162:195–202PubMedGoogle Scholar
  53. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336CrossRefPubMedGoogle Scholar
  54. Stroobants S, Verschakelen J, Vansteenkiste J (2003) Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol 45:49–59CrossRefPubMedGoogle Scholar
  55. Timms B (2000) Positron-emission tomography (PET) superior to computed tomography for staging and detecting metastasis. Eur J Cancer 36:1888Google Scholar
  56. Toloza EM, Harpole L, McCrory DC (2003) Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123(1 suppl):137S–146SCrossRefPubMedGoogle Scholar
  57. Townsend DW, Beyer T (2002) A combined PET/CT scanner: the path to true image fusion. Br J Radiol 75 Spec No:24–30PubMedGoogle Scholar
  58. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. (1995) Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 60:1573–1581CrossRefPubMedGoogle Scholar
  59. Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393CrossRefPubMedGoogle Scholar
  60. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL, et al. (1997) Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 112:1480–1486PubMedGoogle Scholar
  61. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK (1998) Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 9:1193–1198CrossRefPubMedGoogle Scholar
  62. Verboom P, Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, et al. (2003) Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nud Med Mol Imaging 30:1444–1449CrossRefGoogle Scholar
  63. Vesselle HJ, Miraldi FD (1998) FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 18:805–823PubMedGoogle Scholar
  64. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. (2000) Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6:3837–3844PubMedGoogle Scholar
  65. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB (1994) Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191:371–377PubMedGoogle Scholar
  66. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657CrossRefPubMedGoogle Scholar
  67. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W (2001) Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51:56–61CrossRefGoogle Scholar
  68. Yasukawa T, Yoshikawa K, Aoyagi H, Yamamoto N, Tamura K, Suzuki K, et al. (2000) Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 41:283–290PubMedGoogle Scholar
  69. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A (2001) 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795–1799PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Michael P. MacManus
    • 1
  • Rodney J. Hicks
    • 2
  1. 1.Department of Radiation OncologyPeter MacCallum Cancer CentreEast MelbourneAustralia
  2. 2.Centre for Molecular ImagingPeter MacCallum Cancer InstituteEast MelbourneAustralia

Personalised recommendations